SEARLE & CO.

The fortune traces to G.D. Searle, LLC, the pharmaceutical company founded in 1888 that developed blockbuster drugs including Dramamine and Metamucil, and discovered aspartame (NutraSweet). Monsanto acquired the company in 1985 for $2.7 billion, creating the liquidity pool that funds the family office today.

No. Searle & Co. operates as a single-family office, managing capital exclusively for descendants of the G.D. Searle family. It does not solicit outside capital, market investment products, or function as an asset manager open to third-party limited partners.

The firm pursues a multi-asset approach spanning public equities, private equity fund commitments, direct co-investments, venture capital, and real assets. The mandate emphasizes long-term capital preservation across market cycles, consistent with a multi-generational family office with no external redemption pressure.

While the family no longer owns an operating pharmaceutical company, the office has historically maintained significant public-equity positions in healthcare and pharma. The broader portfolio has diversified substantially since the 1980s to include exposures across industries, though healthcare remains a sector where the family retains domain expertise.

Governance details are not publicly disclosed. It is assumed that Searle family members occupy the key decision-making roles on the investment committee, likely supported by a small team of internal investment professionals and external advisors, though the formal structure and succession plan remain private.